Form 4: J&J Executive Wengel Boosts Equity Holdings
Insider Transaction Report
Johnson & Johnson's EVP, Chief TO and Risk Officer, Kathryn E. Wengel, reported significant equity compensation transactions, including RSU and PSU vesting and new option grants.
Summary
- Kathryn E. Wengel, EVP, Chief TO and Risk Officer at Johnson & Johnson, reported multiple transactions related to her equity compensation.
- On February 13, 2026, Wengel acquired 651 shares of Common Stock from Restricted Share Unit (RSU) vesting and 13,706 shares from Performance Share Unit (PSU) vesting.
- A total of 217 shares and 6,414 shares were disposed of on February 13, 2026, at a price of $244.55 per share, to cover tax obligations upon vesting.
- On February 15, 2026, Wengel acquired an additional 606 shares and 635 shares from RSU vesting.
- Another 310 shares and 325 shares were disposed of on February 15, 2026, at a price of $243.45 per share, for tax payments.
- Wengel was awarded 16,945 Employee Stock Options with an exercise price of $243.45 and 1,217 new Restricted Share Units on February 15, 2026.
- Following these transactions, Wengel directly beneficially owns 114,287.8735 shares of Common Stock, with additional indirect holdings of 86 shares via 401k and 281 shares via ESOP.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a routine report of executive equity compensation, reflecting ongoing incentive alignment and standard tax-related share dispositions. The award of new equity suggests continued confidence in the executive's role.
Positives
- The executive's continued acquisition of common stock through vesting of RSUs and PSUs aligns her interests with long-term shareholder value.
- The award of new Employee Stock Options and Restricted Share Units demonstrates ongoing long-term incentive compensation for a key executive.
Negatives
- A significant number of shares were disposed of to cover tax obligations upon vesting, which is a routine but reduces direct share ownership.
Future Outlook
The filing indicates future vesting events for Restricted Share Units awarded in 2023, 2024, 2025, and 2026, as well as for Performance Share Units from 2023 and Employee Stock Options from 2026, all vesting in annual installments over several years.
Industry Context
StockSavvy.ai notes that equity compensation, including Restricted Share Units, Performance Share Units, and stock options, is a standard practice in large pharmaceutical and consumer health companies like Johnson & Johnson. These long-term incentive plans are designed to align executive performance with shareholder interests and promote retention.
Comparison to Industry Standards
- StockSavvy.ai observes that Johnson & Johnson's use of a diversified equity compensation structure, including RSUs, PSUs, and stock options with multi-year vesting schedules, is consistent with best practices for executive compensation in global blue-chip companies.
- For instance, peers such as Pfizer (PFE) and Merck (MRK) also employ similar long-term incentive programs to incentivize and retain key executives, typically involving a mix of performance-based and time-based equity awards.
Stakeholder Impact
- Shareholders: The transactions align the executive's financial interests with shareholder value through increased equity ownership.
- Executive: The transactions represent a significant component of the executive's long-term incentive compensation, increasing her personal equity stake in the company.
Next Steps
- Future annual vesting of Restricted Share Units awarded on February 13, 2023, February 15, 2024, February 15, 2025, and February 15, 2026.
- Future conversion of Performance Share Units awarded on February 13, 2023, upon vesting.
- Future annual vesting of Employee Stock Options awarded on February 15, 2026.
Key Dates
| Date | Description |
|---|---|
| 02/13/2023 | Grant date for Restricted Share Units (RSUs) that vest in three annual equal installments. |
| 02/13/2023 | Grant date for Performance Share Units (PSUs) that convert into shares upon vesting. |
| 02/15/2024 | Grant date for Restricted Share Units (RSUs) that vest in three annual equal installments. |
| 02/15/2025 | Grant date for Restricted Share Units (RSUs) that vest in three annual equal installments. |
| 01/31/2026 | Most recent reporting date for Johnson & Johnson Savings Plan (401k and ESOP). |
| 02/13/2026 | Transaction date for RSU and PSU vesting and associated tax withholding. |
| 02/15/2026 | Transaction date for RSU vesting, new stock option and RSU awards, and associated tax withholding. |
| 02/18/2026 | Signature date of the Form 4 filing. |
| 02/15/2036 | Expiration date for Employee Stock Options awarded on February 15, 2026. |
Recommendation
holdThe filing details routine executive equity compensation, including the vesting of prior awards and new grants of stock options and restricted share units, along with standard tax-related share dispositions. These transactions are part of a pre-established long-term incentive plan and do not indicate a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this report.
Keywords
Johnson & Johnson, JNJ, Form 4, insider transaction, equity compensation, RSU, PSU, stock options, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.